Business Context and Reporting Period
Alterity Therapeutics Limited, a development stage enterprise, filed this Form 6-K for the month of August 2024. The registrant is headquartered in Melbourne, Australia, and files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate action rather than a financial statement.
Material Changes
The primary material change disclosed is the cessation of securities trading for the ticker symbol "ATH," as detailed in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors. The document is a procedural filing to notify the SEC of the cessation of securities and to incorporate this notification by reference into existing Registration Statements on Forms S-8 and F-3.
Investor Verification Checklist
- Verify the effective date and reason for the cessation of securities trading for ticker "ATH."
- Confirm the status of the company's ongoing development stage operations.
- Review the referenced Registration Statements (S-8 and F-3) for any impact on outstanding equity plans.